Decreased dopamine transporter availability in male smokers - A dual isotope SPECT study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 1, 2008, Pages 274-279

  Yang, Yen Kuang ^a,b   Yao, Wei Jen ^b   Yeh, Tzung Lieh ^a,b   Lee, I Hui ^a,b   Chen, Po See ^a,b   Lu, Ru Band ^a,b   Chiu, Nan Tsing ^b  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

D2 D3 receptor; Dopamine transporter; Neuroimaging; Smoking

Indexed keywords

[2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE TRANSPORTER; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE I 123; RADIOISOTOPE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN FUNCTION; CIGARETTE SMOKING; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC ACTIVITY; HUMAN; MALE; PRESYNAPTIC NERVE; QUESTIONNAIRE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMOKING; TOBACCO DEPENDENCE;

ADULT; BENZAMIDES; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; INTERVIEW, PSYCHOLOGICAL; IODINE ISOTOPES; MALE; ORGANOTECHNETIUM COMPOUNDS; PSYCHIATRIC STATUS RATING SCALES; PYRROLIDINES; RECEPTORS, DOPAMINE D2; SMOKING; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 38349130779     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.08.018     Document Type: Article

References (45)

1. 11C]raclopride. Synapse 54 (2004) 65-71
2. Brody A.L. Functional brain imaging of tobacco use and dependence. J Psychiatr Res 40 (2006) 404-418
3. Brody A.L., Olmstead R.E., London E.D., Farahi J., Meyer J.H., and Grossman P. Smoking-induced ventral striatum dopamine release. Am J Psychiatry 161 (2004) 1211-1218
4. Ciliax B.J., Heilman C., Demchyshyn L.L., Pristupa Z.B., Ince E., Hersch S.M., et al. The dopamine transporter: immunochemical characterization and localization in brain. J Neurosci 15 (1995) 1714-1723
5. Czermak C., Lehofer M., Wagner E.M., Prietl B., Gorkiewicz G., Lemonis L., et al. Reduced dopamine D3 receptor expression in blood lymphocytes of smokers is negatively correlated with daily number of smoked cigarettes: a peripheral correlate of dopaminergic alterations in smokers. Nicotine Tob Res 6 (2004) 49-54
6. Court J.A., Lloyd S., Thomas N., Piggott M.A., Marshall E.F., Morris C.M., et al. Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use. Neuroscience 87 (1998) 63-78
7. Dewey S.L., Brodie J.D., Gerasimov M., Horan B., Gardner E.L., and Ashby Jr. C.R. A pharmacologic strategy for the treatment of nicotine addiction. Synapse 31 (1999) 76-86
8. Dresel S.H., Kung M.P., Huang X.F., Plossl K., Hou C., and Meegalla S.K. Simultaneous SPECT studies of pre- and post-synaptic dopamine binding sites in baboons. J Nucl Med 40 (1999) 660-666
9. Fowler J.S., Volkow N.D., Wang G.J., Pappas N., Logan J., and MacGregor R. Inhibition of monoamine oxidase B in the brains of smokers. Nature 379 (1996) 733-736
10. Fowler J.S., Logan J., Wang G.J., Volkow N.D., Telang F., and Zhu W. Low monoamine oxidase B in peripheral organs in smokers. Proc Natl Acad Sci U S A 100 (2003) 11600-11605
11. Fowler J.S., Logan J., Wang G.J., Volkow N.D., Telang F., and Zhu W. Comparison of monoamine oxidase a in peripheral organs in nonsmokers and smokers. J Nucl Med 46 (2005) 1414-1420
12. Freed C., Revay R., Vaughan R.A., Kriek E., Grant S., Uhl G.R., et al. Dopamine transporter immunoreactivity in rat brain. J Comp Neurol 359 (1995) 340-349
13. Haddock C.K., Lando H., Klesges R.C., Talcott G.W., and Renaud E.A. A study of the psychometric and predictive properties of the Fagerstrom Test for Nicotine Dependence in a population of young smokers. Nicotine Tob Res 1 (1999) 59-66
14. Heatherton T.F., Kozlowski L.T., Frecker R.C., and Fagerstrom K.O. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86 (1991) 1119-1127
15. Hersch S.M., Yi H., Heilman C.J., Edwards R.H., and Levey A.I. Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra. J Comp Neurol 388 (1997) 211-227
16. 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease. J Nucl Med 45 (2004) 207-213
17. Iversen L.L. Smoking is harmful to the brain. Nature 382 (1996) 206-207
18. 99mTc]TRODAT-1/[123I]-IBZM simultaneous dual-isotope SPECT in studying pre- and post-synaptic dopamine binding sites: from Phantom Studies to Clinical Applications. Report of: Atomic Energy Council (2001)
19. Kimmel H.L., Joyce A.R., Carroll F.I., and Kuhar M.J. Dopamine D1 and D2 receptors influence dopamine transporter synthesis and degradation in the rat. J Pharmacol Exp Ther 298 (2001) 129-140
20. Kozlowski L.T., Porter C.Q., Orleans C.T., Pope M.A., and Heatherton T. Predicting smoking cessation with self-reported measures of nicotine dependence: FTQ, FTND, and HIS. Drug Alcohol Depend 34 (1994) 211-216
21. Krause K.H., Dresel S.H., Krause J., Kung H.F., and Tatsch K. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett 285 (2000) 107-110
22. Krause K.H., Dresel S.H., Krause J., la Fougere C., and Ackenheil M. Stimulant-like action of nicotine on striatal dopamine transporter in the brain of adults with attention deficit hyperactivity disorder. Int J Neuropsychopharmacol 5 (2002) 111-113
23. Krause K.H., Dresel S.H., Krause J., la Fougere C., and Ackenheil M. The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder. Neurosci Biobehav Rev 27 (2003) 605-613
24. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20 (2000) 423-451
25. Lerman C., Caporaso N.E., Audrain J., Main D., Bowman E.D., Lockshin B., et al. Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol 18 (1999) 14-20
26. 3H]raclopride. Proc Natl Acad Sci U S A 86 (1989) 6412-6416
27. Newberg A., Lerman C., Wintering N., Ploessl K., and Mozley P.D. Dopamine transporter binding in smokers and nonsmokers. Clin Nucl Med 32 (2007) 452-455
28. Nisell M., Nomikos G.G., and Svensson T.H. Nicotine dependence, midbrain dopamine systems and psychiatric disorders. Pharmacol Toxicol 76 (1995) 157-162
29. Piccini P.P. Dopamine transporter: basic aspects and neuroimaging. Mov Disord 18 Suppl 7 (2003) S3-S8
30. Pomerleau O.F., Downey K.K., Stelson F.W., and Pomerleau C.S. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse 7 (1995) 373-378
31. Pontieri F.E., Tanda G., Orzi F., and Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 382 (1996) 255-257
32. Riccio C.A., Reynolds C.R., and Lowe P. Diagnostic efficacy of CPTs in clinical applications of continuous performance tests - measuring attention and impulsive responding in children and adults (2001), John Wiley & Son Inc., New York 193-194
33. Rose J.E., Behm F.M., Westman E.C., Mathew R.J., London E.D., Hawk T.C., et al. PET studies of the influences of nicotine on neural systems in cigarette smokers. Am J Psychiatry 160 (2003) 323-333
34. Sabol S.Z., Nelson M.L., Fisher C., Gunzerath L., Brody C.L., Hu S., et al. A genetic association for cigarette smoking behavior. Health Psychol 18 (1999) 7-13
35. Salokangas R.K., Vilkman H., Ilonen T., Taiminen T., Bergman J., Haaparanta M., et al. High levels of dopamine activity in the basal ganglia of cigarette smokers. Am J Psychiatry 157 (2000) 632-634
36. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 20 (1998) 22-33
37. Stein E.A., Pankiewicz J., Harsch H.H., Cho J.K., Fuller S.A., Hoffmann R.G., et al. Nicotine-induced limbic cortical activation in the human brain: a functional MRI study. Am J Psychiatry 155 (1998) 1009-1015
38. Seibyl J.P., Woods S.W., Zoghbi S.S., Baldwin R.M., Dey H.M., Goddard A.W., et al. Dynamic SPECT imaging of dopamine D2 receptors in human subjects with iodine-123-IBZM. J Nucl Med 33 (1992) 1964-1971
39. Uhl G.R., Hall F.S., and Sora I. Cocaine, reward, movement and monoamine transporters. Mol Psychiatry 7 (2002) 21-26
40. Vles J.S., Feron F.J., Hendriksen J.G., Jolles J., van Kroonenburgh M.J., and Weber W.E. Methylphenidate down-regulates the dopamine receptor and transporter system in children with attention deficit hyperkinetic disorder (ADHD). Neuropediatrics 34 (2003) 77-80
41. Volkow N.D., Wang G.J., Fowler J.S., Gatley S.J., Logan J., Ding Y.S., et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 155 (1998) 1325-1331
42. 99mTc-ECD SPET. Eur J Nucl Med Mol Imaging 30 (2003) 612-614
43. Yang Y.K., McEvoy J.P., Wilson W.H., Levin E.D., and Rose J.E. Reliabilities and intercorrelations of reported and objective measures of smoking in patients with schizophrenia. Schizophr Res 60 (2003) 9-12
44. Yang Y.K., Lung Y., Yeh T.L., Chu C.L., Lee I.H., and Chen P.S. Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study. Am J Psychiatry 161 (2004) 1496-1498
45. Yang Y.K., Yao W.J., McEvoy J.P., Chu C.L., Lee I.H., Chen P.S., et al. Striatal dopamine D2/D3 receptor availability in male smokers. Psychiatry Res 146 (2006) 87-90